Comparison of centrally mediated hypotensive action of methyldopa and DOPA in cats.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000596:Amino Acids / Q000037:antagonists & inhibitors; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001565:Benzoates / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D002230:Carbidopa / Q000494:pharmacology; D002415:Cats; D002552:Cerebral Ventricles; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D004220:Disulfides / Q000494:pharmacology; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D005260:Female; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D008750:Methyldopa / Q000494:pharmacology*; D010477:Perfusion; D010646:Phentolamine / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D000596:Amino Acids; D000959:Antihypertensive Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001565:Benzoates; D004220:Disulfides; D007093:Imidazoles; D011743:Pyrimidines; D013141:Spiro Compounds; D013438:Sulfhydryl Compounds; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D004299:Dopamine beta-Hydroxylase; D002230:Carbidopa; D010646:Phentolamine